THC and CBD concentrations in blood, oral fluid and urine following a single and repeated administration of "light cannabis"

被引:44
|
作者
Pacifici, Roberta [1 ]
Pichini, Simona [1 ]
Pellegrini, Manuela [1 ]
Rotolo, Maria Concetta [1 ]
Giorgetti, Raffaele [2 ]
Tagliabracci, Adriano [2 ]
Busardo, Francesco Paolo [2 ]
Huestis, Marilyn A. [3 ]
机构
[1] Ist Super Sanita, Natl Ctr Addict & Doping, Vle Regina Elena 299, I-00161 Rome, Italy
[2] Univ Politecn Marche, Sect Legal Med, Ancona, Italy
[3] Thomas Jefferson Univ, Inst Emerging Hlth Profess, Lambert Ctr Study Med Cannabis & Hemp, Philadelphia, PA 19107 USA
关键词
Delta(9)-tetrahydrocannabinol (THC); blood; light cannabis; oral fluid; urine; variable cannabidiol (CBD); WHOLE-BLOOD; SMOKERS; PLASMA; FREQUENT; SMOKING; SALIVA; DRUGS; ABUSE;
D O I
10.1515/cclm-2019-0119
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: "Light cannabis" is a product legally sold in Europe with Delta 9-tetrahydrocannabinol (THC) concentration lower than 0.2% and variable cannabidiol (CBD) content. We studied THC and CBD excretion profiles in blood, oral fluid (OF) and urine after smoking one or four light cannabis cigarettes. Methods: Blood, OF and urine samples were obtained from six healthy light cannabis consumers after smoking one 1 g cigarette containing 0.16% THC and 5.8% CBD and from six others after smoking four 1 g cigarettes within 4 h. Sample collection began 0.5 and 4.5 h after smoking one or four cigarettes, respectively. Cannabinoid concentrations were quantified by gas chromatography-mass spectrometry (GC-MS). Results: At the first collection, the highest THC and CBD concentrations occurred in blood (THC 7.0-10.8 ng/mL; CBD 30.2-56.1 ng/mL) and OF (THC 5.1-15.5 ng/mL; CBD 14.2-28.1 ng/mL); similar results occurred 0.5 h after the last of four cigarettes in blood (THC 14.1-18.2 ng/mL, and CBD 25.6-45.4 ng/mL) and OF (THC 11.2-24.3 ng/mL; CBD 14.4-37.0 ng/mL). The mean OF to blood ratio ranged from 0.6 to 1.2 after one and 0.6 to 1.9 after four light cannabis cigarettes. THC/CBD ratios in blood and OF were never greater than 2. Urinary 11-nor-9-carboxy-THC concentrations peaked 8 h after one and four cigarettes. Conclusions: OF was a valuable alternative to blood in monitoring consumption of light cannabis. Blood and OF THC/CBD concentration ratios, never exceeded 2, possibly providing a useful biomarker to identify light cannabis vs illegal higher THC cannabis use, where THC/CBD ratios are generally greater than 10.
引用
收藏
页码:682 / 689
页数:8
相关论文
共 50 条
  • [21] Whole Blood/Plasma Ratios in Ten Chronic Cannabis Users after Frequent Oral THC Administration
    Karschner, Erin L.
    Schwope, David M.
    Schwilke, Eugene W.
    Gorelick, David A.
    Goodwin, Robert S.
    Lowe, Ross H.
    Kelly, Deanna L.
    Huestis, Marilyn A.
    THERAPEUTIC DRUG MONITORING, 2009, 31 (05) : 606 - 606
  • [22] Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana
    Niedbala, RS
    Kardos, KW
    Fritch, DF
    Kardos, S
    Fries, T
    Waga, J
    Robb, J
    Cone, EJ
    JOURNAL OF ANALYTICAL TOXICOLOGY, 2001, 25 (05) : 289 - 303
  • [23] On-site oral fluid Δ9-tetrahydrocannabinol (THC) screening after controlled smoked, vaporized, and oral cannabis administration
    Madeleine J. Swortwood
    Matthew N. Newmeyer
    Osama A. Abulseoud
    Maria Andersson
    Allan J. Barnes
    Karl B. Scheidweiler
    Marilyn A. Huestis
    Forensic Toxicology, 2017, 35 : 133 - 145
  • [24] BLOOD CONCENTRATIONS AND CLINICAL RESULTS FOLLOWING THE ORAL ADMINISTRATION OF PENICILLIN
    GREEY, P
    HENNESSY, J
    HOGARTH, J
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 1954, 71 (04) : 335 - 338
  • [25] CONCENTRATIONS OF QUINIDINE IN BLOOD FOLLOWING ORAL, PARENTERAL AND RECTAL ADMINISTRATION
    DITLEFSEN, EML
    ACTA MEDICA SCANDINAVICA, 1953, 146 (02): : 81 - 92
  • [26] On-site oral fluid Δ9-tetrahydrocannabinol (THC) screening after controlled smoked, vaporized, and oral cannabis administration
    Swortwood, Madeleine J.
    Newmeyer, Matthew N.
    Abulseoud, Osama A.
    Andersson, Maria
    Barnes, Allan J.
    Scheidweiler, Karl B.
    Huestis, Marilyn A.
    FORENSIC TOXICOLOGY, 2017, 35 (01) : 133 - 145
  • [27] Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?
    Lee, Dayong
    Karschner, Erin L.
    Milman, Garry
    Barnes, Allan J.
    Goodwin, Robert S.
    Huestis, Marilyn A.
    DRUG AND ALCOHOL DEPENDENCE, 2013, 130 (1-3) : 68 - 76
  • [28] Plasma and urine concentrations of Marbofloxacin following single subcutaneous administration to cats
    Kietzmann, Manfred
    Niedorf, Frank
    Kramer, Sabine
    Hoffmann, Marina
    Schneider, Marc
    Valle, Marc
    Pankow, Ruediger
    BERLINER UND MUNCHENER TIERARZTLICHE WOCHENSCHRIFT, 2011, 124 (1-2): : 83 - 88
  • [29] Acute Effects of a Single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers
    Martin-Santos, R.
    Crippa, J. A.
    Batalla, A.
    Bhattacharyya, S.
    Atakan, Z.
    Borgwardt, S.
    Allen, P.
    Seal, M.
    Langohr, K.
    Farre, M.
    Zuardi, A. W.
    McGuire, P. K.
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (32) : 4966 - 4979
  • [30] Urinary Pharmacokinetic Profile of Cannabinoids Following Administration of Vaporized and Oral Cannabidiol and Vaporized CBD-Dominant Cannabis
    Spindle, Tory R.
    Cone, Edward J.
    Kuntz, David
    Mitchell, John M.
    Bigelow, George E.
    Flegel, Ron
    Vandrey, Ryan
    JOURNAL OF ANALYTICAL TOXICOLOGY, 2020, 44 (02) : 109 - 125